Frequently Asked Questions about Akari Therapeutics, Plc (AKTX)

Name: Akari Therapeutics, Plc (AKTX) Institutional Financial Dataset
Creator: Olyth
License: https://olyth.xyz

Question 1

What does Akari Therapeutics, Plc (AKTX) do?

Accepted Answer

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including...

Question 2

Is Akari Therapeutics, Plc (AKTX) a good stock to buy?

Accepted Answer

Olyth's institutional analysis of AKTX reveals an Altman Z-Score of -8.91 and a Piotroski F-Score of 2/9. These metrics, combined with its 5-year revenue trend ($0.00B most recent), help investors decide if AKTX fits their risk profile.

Question 3

What is the current P/E ratio for AKTX?

Accepted Answer

As of the latest trading session, Akari Therapeutics, Plc (AKTX) has a trailing P/E ratio of -0.17.

Question 4

Who is the CEO of Akari Therapeutics, Plc?

Accepted Answer

The current Chief Executive Officer of Akari Therapeutics, Plc is Abizer Gaslightwala.

Question 5

What was AKTX's revenue for the last 5 years?

Accepted Answer

According to its latest income statements, Akari Therapeutics, Plc reported annual revenues of $0.00B (2025), $0.00B (2024), $0.00B (2023), $0.00B (2022), $0.00B (2021) respectively.

Question 6

Does AKTX pay a dividend?

Accepted Answer

Akari Therapeutics, Plc does not currently pay a dividend to its shareholders.

Question 7

How much debt and cash flow does AKTX have?

Accepted Answer

In its latest reporting period, Akari Therapeutics, Plc generated $-0.01B in Free Cash Flow against a total debt load of $0.00B.

Question 8

What is the Price-to-Book (P/B) ratio of Akari Therapeutics, Plc?

Accepted Answer

The Price-to-Book (P/B) ratio for Akari Therapeutics, Plc (AKTX) is currently 0.11.

Question 9

What is the Price-to-Sales (P/S) ratio of AKTX?

Accepted Answer

Based on trailing twelve-month data, Akari Therapeutics, Plc (AKTX) trades at a Price-to-Sales (P/S) ratio of 0.00.

Question 10

What is Akari Therapeutics, Plc's Return on Equity (ROE)?

Accepted Answer

Akari Therapeutics, Plc (AKTX) has a Return on Equity (ROE) of -70.34%, representing its profitability relative to shareholder equity.